By Fineline Cube 
China-based Robo Medical Technology Co. has closed a strategic funding round amounting to “tens of millions” of yuan, led by Yuan Chang Fund under Fenglei Capital, with participation from Tai Kun Fund and exclusive financial counsel from Mai Bai Capital. The proceeds will be used to support product iteration, overseas expansion, and the recruitment of top-tier talent.
Funding Priorities
The funds will be allocated to three key areas:
- Upgrading the EndoFaster platform and accelerating the development of the next-generation EndoDreams system.
- Enhancing production capacity and optimizing supply chains to rebuild a global med-tech ecosystem.
- Deepening clinical partnerships with leading hospitals worldwide to expedite validation and adoption of Robo Medical’s technologies.
EndoFaster Platform
Robo Medical’s flagship product, the EndoFaster platform, integrates bimanual cooperation, full visualization, and sub-millimeter accuracy to enhance efficiency in early-stage cancer minimally invasive therapy. The company plans to expand its applications from gastroenterology into urology and gynecology, while also entering new markets in Asia, Latin America, and Eastern Europe.-Fineline Info & Tech